查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1641794

全球疫苗佐剂市场（按类型、疾病和应用）机会分析和产业预测，2024-2035 年

Vaccine Adjuvants Market By Type (Immunostimulants, Vehicles and Mucosal Adjuvants), By Disease (Infectious Diseases, Others), By Application (Research, Commercial): Global Opportunity Analysis and Industry Forecast, 2024-2035
出版日期: | 出版商: Allied Market Research | 英文 339 Pages | 商品交期: 2-3个工作天内

价格
简介目录

疫苗佐剂市场规模预计在 2023 年将达到 8.202 亿美元，到 2035 年将达到 13.0483 亿美元，2024 年至 2035 年的复合年增长率为 3.9%。

疫苗佐剂是一种添加到疫苗中的物质，用于增强人体对目标抗原的免疫反应，从而产生更强、更快、更持久的免疫力。从功能上看，佐剂透过模仿感染讯号发挥作用，透过刺激免疫细胞或活化特定的免疫途径促使免疫系统产生保护性反应。这种反应可以提高疫苗的有效性，并减少抗原的数量或接种次数。载体佐剂增加抗原的稳定性和运输，增强免疫系统的辨识和反应。

疫苗佐剂市场-IMG1

佐剂的优点是能够增强老年人和免疫力缺乏的个体的免疫力，并提供多种病原体的广泛保护。佐剂类型包括铝盐（明矾），由于其安全性和有效性而被广泛使用；油包水乳剂，如MF59和AS03，可增强抗原的吸收；以及较新的类型，如基于脂质体、皂素和奈米颗粒的佐剂，可提供靶向递送和控制释放。佐剂类型在有效疫苗的开发中起着关键作用，因为它们是根据其增强特异性目标疾病的免疫反应的能力来选择的。

疫苗佐剂市场受到对更有效疫苗日益增长的需求的推动，特别是针对新出现的感染疾病和慢性病。流感、肝炎、新冠肺炎和各种细菌感染疾病等感染疾病率的不断上升推动了对疫苗的需求，凸显了对提供广泛保护的创新疫苗解决方案的需求。例如，根据世界卫生组织（WHO）2023年发表的一篇论文，西太平洋地区有1.16亿人患有B型肝炎，1000万人患有C型肝炎。这一发病率凸显了对有效疫苗和支持免疫反应的佐剂的持续需求，特别是在高风险族群中，从而推动了疫苗佐剂市场的成长。

疫苗佐剂可以增强对抗原的免疫反应，潜在地提高疫苗的有效性并减少所需的剂量，这在医疗保健有限的地区尤其有益。此外，政府资金和支持疫苗开发的倡议也在疫苗佐剂市场的成长中发挥重要作用。世界卫生组织（WHO）等组织和各国政府正投入疫苗研究和生产，以提高全球免疫率。例如，2023年8月，美国卫生与公众服务部宣布透过NextGen计画提供超过14亿美元的资金。其中包括10亿美元用于疫苗临床试验、3.26亿美元用于新型单株抗体疗法，以及1亿美元用于研究新型疫苗技术，以推进COVID-19疫苗开发和治疗方法。

此外，製药公司和研究机构之间日益增多的合作也促进了功效和安全性更高的新型佐剂的开发。例如，2023 年 10 月，SPI Pharma, Inc. (SPI) 和 Q-Vant Biosciences, Inc. 合作，利用 Q-Vant 在独特和永续皂素萃取技术方面的领导地位，将 SPI 的服务和专业知识提供给全球製药业。扩大高纯度皂素商业规模 GMP 生产的投资承诺和独家商业协议将确保全球製药公司能够获得永续和完全整合的皂素佐剂供应。此类伙伴关係正在加速研发，推动疫苗佐剂市场的成长。

然而，预计与研究、开发和生产相关的高成本将抑制市场成长。佐剂开发需要大量投入专门的技术，并进行严格的测试以确保安全性和有效性，这增加了生产成本。对于许多公司来说，这些高昂的初始成本构成了进入壁垒，限制了市场参与企业并减少了竞争。此外，疫苗佐剂的监管要求严格，特别是在核准标准严格的地区，这进一步限制了市场的成长。

然而，新兴经济体疫苗接种计划的不断增加以及对个人化和治疗性疫苗的关注进一步增强了市场的成长机会。随着越来越多的製药和生技公司开始投资新的辅助技术，以满足多样化和日益增长的医疗保健需求。此外，疫苗研发的进步和新兴国家的高成长潜力为市场成长提供了机会。

疫苗佐剂市场根据类型、疾病、应用和地区进行细分。根据类型，市场分为免疫刺激剂和载体/黏膜佐剂。活化部分进一步分为 Toll 样受体 (TLR) 和其他。根据疾病，市场分为感染疾病和其他疾病。感染疾病部分进一步分为肝炎和其他疾病。根据应用，市场分为研究和商业。依照地区，分析分为北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙和其他欧洲国家地区）、亚太地区（日本、中国、印度、澳洲、韩国和其他亚太地区）、拉丁美洲（巴西、哥伦比亚、阿根廷和其他拉丁美洲地区）以及中东和美洲（海湾合作委员会、阿根廷和其他拉丁美洲地区）。

相关人员的主要利益

  • 该报告对 2023 年至 2035 年疫苗佐剂市场的细分市场、当前趋势、估计和动态进行了定量分析，并确定了疫苗佐剂市场的突出市场机会。
  • 它为市场研究提供与市场驱动因素、市场限制因素和市场机会相关的资讯。
  • 波特五力分析强调了买家和供应商的潜力，使相关人员能够做出利润驱动的商业决策并加强供应商-买家网络。
  • 对疫苗佐剂市场区隔的详细分析有助于确定市场机会。
  • 每个地区的主要国家都根据收益贡献进行划分。
  • 市场公司的定位有利于基准化分析，并能清楚了解市场公司的当前地位。
  • 报告包括区域和全球疫苗佐剂市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

此报告可进行客製化（需支付额外费用和时间表）

  • 国家、地区和全球层面的患者/流行病学资料
  • 监管指南
  • 根据客户兴趣提供额外的公司简介
  • 按国家或地区进行的额外分析 - 市场规模和预测
  • 扩展公司简介列表
  • 历史市场资料
  • SWOT 分析

目录

第 1 章 简介

第 2 章执行摘要

第三章 市场概况

  • 市场定义和范围
  • 主要发现
    • 关键影响因素
    • 重大投资机会
  • 波特五力分析
  • 市场动态
    • 驱动程式
      • 感染疾病率上升
      • 扩大疫苗和感染疾病资金投入
      • 扩大疫苗接种计划
    • 限制因素
      • 初期及研发成本高
    • 机会
      • 新兴市场的成长机会
      • 疫苗佐剂研究进展

第四章 疫苗佐剂市场类型

  • 概述
  • 活化
    • 活化疫苗佐剂市场（按类型）
  • 载体/黏膜佐剂

第 5 章 疫苗佐剂市场（依疾病）

  • 概述
  • 感染疾病
    • 感染疾病疫苗佐剂市场（按类型）
  • 其他的

第六章疫苗佐剂市场（依应用）

  • 概述
  • 研究
  • 商业的

7. 疫苗佐剂市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 阿根廷
    • 其他拉丁美洲国家
  • 中东和非洲
    • Gcc
    • 南非
    • 北非
    • 其他中东和非洲地区

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 前 10 家公司的产品图谱
  • 竞争仪錶板
  • 竞争热图
  • 2023年主要企业的定位

第九章 公司简介

  • Dynavax Technologies Corporation
  • Novovax Inc.
  • Agenus Inc.
  • Adjuvatis
  • Aurorium
  • InvivoGen
  • Croda International Plc
  • Air Liquide Group
  • Associated British Foods
  • GlaxoSmithKline plc.
简介目录
Product Code: A01341

The vaccine adjuvants market was valued at $820.2 million in 2023 and is estimated to reach $1,304.83 million by 2035, exhibiting a CAGR of 3.9% from 2024 to 2035.

Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the target antigen, allowing for a stronger, faster, or more prolonged immunity. Functionally, adjuvants work by stimulating immune cells or activating specific immune pathways, by mimicking infection signals that prompt the immune system to initiate a protective response. This response can improve the efficacy of vaccines, reducing the amount of antigen needed or the number of doses required. Vehicular adjuvants enhance stability, transport the antigen, and facilitate the immune system's recognition and response.

Vaccine Adjuvants Market - IMG1

Adjuvants offer advantages such as boosting immunity in older or immunocompromised individuals and enabling broad protection against multiple pathogens. Types of adjuvants include aluminum salts (alum), which are widely used for their safety and efficacy; oil-in-water emulsions like MF59 and AS03, which enhance antigen uptake; and novel types such as liposomes, saponins, and nanoparticle-based adjuvants that offer targeted delivery and controlled release. The adjuvant types are selected based on their ability to enhance immune responses specific to the disease being targeted, thus playing a crucial role in developing effective and efficient vaccines.

The vaccine adjuvants market is driven by rise in demand for more effective vaccines, especially in emerging infectious diseases and chronic conditions. Rise in incidence of infectious diseases, including flu, hepatitis, COVID-19, and various bacterial infections, emphasize the need for innovative vaccine solutions that rovide broad protection,thereby driving the demand for vaccines. For instance, according to an article published by World Health Organization (WHO) in 2023, 116 million people were living with hepatitis B and 10 million with hepatitis C in the Western Pacific Region. This incidence highlights the ongoing need for effective vaccines and adjuvants to support immune responses, particularly in high-risk populations, thereby driving the vaccine adjuvants market growth.

Vaccine adjuvants enhance the immune response to antigens, making vaccines more effective and potentially reducing the number of doses required, which is particularly beneficial in regions with limited healthcare access. In addition, the government funding and initiatives supporting vaccine development also play a significant role in the growth of the vaccine adjuvants market. Agencies such as the World Health Organization (WHO) and governments globally are investing in vaccine research and production to improve global immunization rates. For instance, in August 2023, the U.S. Department of Health and Human Services announced over $1.4 billion in funding through Project NextGen. This includes $1 billion for vaccine clinical trials, $326 million for new monoclonal antibody treatments, and $100 million to explore novel vaccine technologies, aimed at advancing COVID-19 vaccine development and therapeutics.

In addition, rise in collaborations between pharmaceutical companies and research institutions is leading to the development of new adjuvants with enhanced efficacy and safety. For instance, in October 2023, SPI Pharma, Inc., (SPI) and Q-Vant Biosciences, Inc. partnered to leverage Q-Vant's leadership in unique, sustainable saponin extraction technology with SPI's global pharmaceutical reach and expertise in servicing the industry. The investment commitment to expand commercial-scale GMP manufacturing of high-purity saponins, along with the exclusive commercial agreement, will enable global pharma customers to access a sustainable, scalable, and fully integrated supply of saponin adjuvants. These partnerships are accelerating research and development, thus propelling the growth of the vaccine adjuvants market.

However, high costs associated with research, development, and production are expected to restrain the market growth. Adjuvant development requires significant investment in specialized technologies and stringent testing to ensure safety and efficacy, which increases manufacturing costs. For many companies, these high initial costs pose a barrier to entry, limiting the number of players in the market and reducing the competitive landscape. In addition, stringent regulatory requirements for vaccine adjuvants, particularly in regions with rigorous approval standards, further restrict the market growth.

However, rise in vaccination programs in emerging countries, along with a focus on personalized and therapeutic vaccines, further enhance growth opportunities for the market, as more pharmaceutical and biotech companies invest in new adjuvant technologies to meet diverse and growing healthcare needs globally. In addition, rise in advancements in vaccine development and high growth potential in emerging countries provide an opportunity for the market growth.

The vaccine adjuvants market is segmented into type, disease, application, and region. By type, the market is bifurcated into immunostimulants and vehicles & mucosal adjuvants. The immunostimulants segment is further classified into toll-like receptor (TLR) and others. By disease, the market is segregated into infectious diseases and others. The infectious diseases segment is further classified into hepatitis and others. By application, the market is bifurcated into research and commercial. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India,Australia, South Korea, and rest of Asia-Pacific), and Latin America (Brazil, Colombia, Argentina, and Rest of LA), and Middle East Africa (GCC, South Africa, North Africa, and Rest of MEA).

Major key players that operate in the global vaccine adjuvants market are Dynavax Technologies Corporation , Novovax, Agenus Inc., Adjuvatis, Air Liquide Group, Aurorium, InvivoGen, Associated British Foods, GlaxoSmithKline plc., and Croda International Plc. Key players operating in the market have adopted agreement, acquisition, partnership, clinical trials, and product approval as their key strategies to expand their product portfolio. For instance, in May 2024, Novavax, Inc. entered into a co-exclusive licensing agreement with Sanofi. The terms of the agreement include a co-exclusive license to co-commercialize Novavax's current stand-alone adjuvanted COVID-19 vaccine worldwide.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vaccine adjuvants market analysis from 2023 to 2035 to identify the prevailing vaccine adjuvants market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vaccine adjuvants market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vaccine adjuvants market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Type

  • Immunostimulants
    • Type
    • Toll like receptor
    • Others
  • Vehicles and Mucosal Adjuvants

By Disease

  • Infectious Diseases
    • Type
    • Hepatitis
    • Others
  • Others

By Application

  • Research
  • Commercial

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest of Latin America
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest of Middle East And Africa

Key Market Players:

    • Agenus Inc.
    • Novovax Inc.
    • Aurorium
    • Air Liquide Group
    • Adjuvatis
    • InvivoGen
    • Associated British Foods
    • GlaxoSmithKline plc.
    • Croda International Plc
    • Dynavax Technologies Corporation

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Moderate intensity of rivalry
    • 3.3.2. Moderate bargaining power of buyers
    • 3.3.3. Moderate bargaining power of suppliers
    • 3.3.4. High threat of new entrants
    • 3.3.5. Moderate threat of substitutes
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increase in prevalence of infectious diseases
      • 3.4.1.2. Growing funding for vaccines and infectious diseases
      • 3.4.1.3. Expansion of vaccination programs
    • 3.4.2. Restraints
      • 3.4.2.1. High initial and R&D cost
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
      • 3.4.3.2. Advancements in vaccine adjuvant research

CHAPTER 4: VACCINE ADJUVANTS MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Immunostimulants
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
    • 4.2.4. Immunostimulants Vaccine Adjuvants Market by Type
  • 4.3. Vehicles and Mucosal Adjuvants
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: VACCINE ADJUVANTS MARKET, BY DISEASE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Infectious Diseases
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
    • 5.2.4. Infectious Diseases Vaccine Adjuvants Market by Type
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: VACCINE ADJUVANTS MARKET, BY APPLICATION

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Research
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Commercial
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country

CHAPTER 7: VACCINE ADJUVANTS MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Type
    • 7.2.3. Market size and forecast, by Disease
    • 7.2.4. Market size and forecast, by Application
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Type
      • 7.2.5.1.2. Market size and forecast, by Disease
      • 7.2.5.1.3. Market size and forecast, by Application
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Type
      • 7.2.5.2.2. Market size and forecast, by Disease
      • 7.2.5.2.3. Market size and forecast, by Application
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Type
      • 7.2.5.3.2. Market size and forecast, by Disease
      • 7.2.5.3.3. Market size and forecast, by Application
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Type
    • 7.3.3. Market size and forecast, by Disease
    • 7.3.4. Market size and forecast, by Application
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Type
      • 7.3.5.1.2. Market size and forecast, by Disease
      • 7.3.5.1.3. Market size and forecast, by Application
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Type
      • 7.3.5.2.2. Market size and forecast, by Disease
      • 7.3.5.2.3. Market size and forecast, by Application
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Type
      • 7.3.5.3.2. Market size and forecast, by Disease
      • 7.3.5.3.3. Market size and forecast, by Application
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Type
      • 7.3.5.4.2. Market size and forecast, by Disease
      • 7.3.5.4.3. Market size and forecast, by Application
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Type
      • 7.3.5.5.2. Market size and forecast, by Disease
      • 7.3.5.5.3. Market size and forecast, by Application
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Type
      • 7.3.5.6.2. Market size and forecast, by Disease
      • 7.3.5.6.3. Market size and forecast, by Application
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Type
    • 7.4.3. Market size and forecast, by Disease
    • 7.4.4. Market size and forecast, by Application
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Type
      • 7.4.5.1.2. Market size and forecast, by Disease
      • 7.4.5.1.3. Market size and forecast, by Application
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Type
      • 7.4.5.2.2. Market size and forecast, by Disease
      • 7.4.5.2.3. Market size and forecast, by Application
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Type
      • 7.4.5.3.2. Market size and forecast, by Disease
      • 7.4.5.3.3. Market size and forecast, by Application
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Type
      • 7.4.5.4.2. Market size and forecast, by Disease
      • 7.4.5.4.3. Market size and forecast, by Application
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Type
      • 7.4.5.5.2. Market size and forecast, by Disease
      • 7.4.5.5.3. Market size and forecast, by Application
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Type
      • 7.4.5.6.2. Market size and forecast, by Disease
      • 7.4.5.6.3. Market size and forecast, by Application
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Type
    • 7.5.3. Market size and forecast, by Disease
    • 7.5.4. Market size and forecast, by Application
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Type
      • 7.5.5.1.2. Market size and forecast, by Disease
      • 7.5.5.1.3. Market size and forecast, by Application
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Type
      • 7.5.5.2.2. Market size and forecast, by Disease
      • 7.5.5.2.3. Market size and forecast, by Application
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Type
      • 7.5.5.3.2. Market size and forecast, by Disease
      • 7.5.5.3.3. Market size and forecast, by Application
      • 7.5.5.4. Rest of Latin America
      • 7.5.5.4.1. Market size and forecast, by Type
      • 7.5.5.4.2. Market size and forecast, by Disease
      • 7.5.5.4.3. Market size and forecast, by Application
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Type
    • 7.6.3. Market size and forecast, by Disease
    • 7.6.4. Market size and forecast, by Application
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Type
      • 7.6.5.1.2. Market size and forecast, by Disease
      • 7.6.5.1.3. Market size and forecast, by Application
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Type
      • 7.6.5.2.2. Market size and forecast, by Disease
      • 7.6.5.2.3. Market size and forecast, by Application
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Type
      • 7.6.5.3.2. Market size and forecast, by Disease
      • 7.6.5.3.3. Market size and forecast, by Application
      • 7.6.5.4. Rest of Middle East And Africa
      • 7.6.5.4.1. Market size and forecast, by Type
      • 7.6.5.4.2. Market size and forecast, by Disease
      • 7.6.5.4.3. Market size and forecast, by Application

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Dynavax Technologies Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. Novovax Inc.
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Agenus Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Adjuvatis
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
  • 9.5. Aurorium
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Key strategic moves and developments
  • 9.6. InvivoGen
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
  • 9.7. Croda International Plc
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Air Liquide Group
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Associated British Foods
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. GlaxoSmithKline plc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments